Highlights
- Net business wins of $510 million; net
book to bill of 1.21.
- Backlog of business grows 11.8% year on
year to $4.25 billion.
- Net revenue increases 6.4% to $420
million in the quarter.
- Income from operations increases 13.7%
to 19.3% of revenue before non-recurring charges.
- Earnings per share increases 17% to
$1.19 before non-recurring charges.
ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today reported its
financial results for the third quarter ended September 30,
2016.
Gross business wins in the third quarter were $572 million and
cancellations in the quarter were $62 million, resulting in net
business wins of $510 million, a net book to bill of 1.21.
In the third quarter net revenue grew 6.4% year on year to
$420.2 million from $394.7 million in the same quarter last
year.
Income from operations, before non-recurring charges in the
quarter, increased by 13.7% to $81.2 million or 19.3% of revenue,
compared to $71.4 million or 18.1% for the same quarter last
year.
Net income, before non-recurring charges in the quarter,
increased by 9.6% to $67.4 million compared with $61.5 million in
the same quarter last year.
Earnings per share, before non-recurring charges, increased to
$1.19 per share on a diluted basis, from $1.02 per share for the
same quarter last year, an increase of 17%.
Year to date revenue for 2016 increased by 5.1% to $1,231.4
million from $1,171.6 million in 2015.
Year to date income from operations for 2016, before
non-recurring charges, increased by 14.1% to $235.2 million or
19.1% of revenue compared with $206.2 million or 17.6% of revenue
in the previous year.
Year to date net income for 2016, before non-recurring charges,
increased by 10.8% to $195.1 million compared with $176.0 million
last year.
Year to date earnings per share before non-recurring charges
increased to $3.45 per share on a diluted basis from $2.85 per
diluted share last year, an increase of 21%.
Day’s sales outstanding, comprising accounts receivable and
unbilled revenue less payments on account, were 50 days at
September 30, 2016, compared with 46 days at the end of June 30,
2016 and 46 days at the end of September 2015.
Cash generated from operating activities for the quarter was $52
million. Capital expenditure for the quarter was $9.5 million and
the acquisition of Clinical Research Management, Inc. was completed
for an initial cash consideration of $52.4 million. As a result, at
September 30, 2016, the company had net debt of $98 million,
compared to net debt of $97 million at June 30, 2016 and net debt
of $31 million at end of September 2015.
During the quarter the company recorded a charge of $4.1 million
in relation to restructuring costs. US GAAP income from operations
after these items amounted to $77.1 million or 18.4% of revenue. US
GAAP net income for the quarter was $63.9 million or $1.13 per
diluted share.
CEO Ciaran Murray commented, “Quarter three was a strong quarter
for ICON. Net business wins were $510 million, representing a book
to bill of 1.21 and our backlog grew by almost 12% over last year
to $4.25 billion. As a result revenue grew 6.4% over the same
quarter last year to $420 million and earnings per share increased
by 17% to $1.19. Our continuing success in winning business,
growing our backlog and diversifying our customer base positions us
well for future growth.”
In addition to the financial measures prepared in accordance
with generally accepted accounting principles (GAAP), this press
release contains certain non-GAAP financial measures, including
non-GAAP operating and net income and non-GAAP diluted earnings per
share. While non-GAAP financial measures are not superior to or a
substitute for the comparable GAAP measures, ICON believes certain
non-GAAP information is useful to investors for historical
comparison purposes.
ICON will hold its third quarter conference call today, October
20, 2016 at 9:00 EDT [14:00 Ireland & UK]. This call and linked
slide presentation can be accessed live from our website at
http://investor.iconplc.com. A recording will also be available on
the website for 90 days following the call. In addition, a calendar
of company events, including upcoming conference presentations, is
available on our website, under “Investors”. This calendar will be
updated regularly.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 88 locations in 37 countries and has approximately
12,600 employees. Further information is available at
www.iconplc.com.
ICON/ICLR-F
ICON plc
Consolidated Income Statements
(Unaudited)
(Before restructuring costs)
Three and Nine Months ended September
30, 2016 and September 30, 2015
(Dollars, in thousands, except share
and per share data)
Three Months Ended Nine Months
Ended September 30,
September 30, September
30, September 30,
2016
2015
2016
2015
Revenue: Gross revenue $622,261 $557,095 $1,754,491 $1,584,559
Reimbursable expenses (202,060) (162,354)
(523,138) (412,930)
Net revenue
420,201 394,741 1,231,353 1,171,629
Costs and
expenses: Direct costs 243,244 226,555 709,831 679,593 Selling,
general and administrative expense 81,235 82,435 242,192 243,310
Depreciation and amortization 14,543 14,366
44,120 42,535
Total costs and
expenses 339,022 323,356 996,143
965,438
Income from operations 81,179
71,385 235,210 206,191 Net interest expense (2,765)
(647) (8,485) (660)
Income before provision for income taxes 78,414 70,738
226,725 205,531 Provision for income taxes (10,978)
(9,196) (31,668) (29,534)
Net income $67,436 $61,542
$195,057 $175,997 Net income per Ordinary
Share: Basic $1.21 $1.05 $3.52
$2.95 Diluted $1.19 $1.02
$3.45 $2.85 Weighted average number of
Ordinary Shares outstanding: Basic 55,734,773
58,659,782 55,355,020 59,728,608
Diluted 56,645,239 60,369,898 56,475,319
61,785,849
Consolidated Income Statements
(Unaudited)
(US GAAP including restructuring
costs)
Three and Nine Months ended September
30, 2016 and September 30, 2015
(Dollars, in thousands, except share
and per share data)
Three Months Ended Nine Months
Ended September 30,
September 30, September
30, September 30,
2016
2015
2016
2015
Revenue: Gross revenue $622,261 $557,095 $1,754,491 $1,584,559
Reimbursable expenses (202,060) (162,354)
(523,138) (412,930)
Net revenue
420,201 394,741 1,231,353 1,171,629
Costs and
expenses: Direct costs 243,244 226,555 709,831 679,593 Selling,
general and administrative expense 81,235 82,435 242,192 243,310
Depreciation and amortization 14,543 14,366 44,120 42,535
Restructuring charge 4,065 - 8,159
-
Total costs and expenses 343,087
323,356 1,004,302 965,438
Income from operations 77,114 71,385 227,051 206,191
Net interest expense (2,765) (647)
(8,485) (660)
Income before
provision for income taxes 74,349 70,738 218,566 205,531
Provision for income taxes (10,470) (9,196)
(30,649) (29,534)
Net income
$63,879 $61,542 $187,917
$175,997 Net income per Ordinary Share: Basic $1.15
$1.05 $3.39 $2.95
Diluted $1.13 $1.02 $3.33
$2.85 Weighted average number of Ordinary Shares
outstanding: Basic 55,734,773 58,659,782
55,355,020 59,728,608 Diluted
56,645,239 60,369,898 56,475,319
61,785,849
ICON plc
Summary Balance Sheet Data
September 30, 2016 and June 30,
2016
(Dollars, in thousands)
September 30, June 30,
2016 2016 (Unaudited) (Unaudited)
Cash and short-term investments 303,720 250,951 Debt
(401,417) (348,322) Net (debt)/cash (97,697) (97,371)
Accounts receivable 403,667 366,903 Unbilled revenue 196,863
190,025 Payments on account (250,833) (257,514) Total 349,697
299,414 Working Capital 550,789 452,073 Total Assets
1,900,478 1,750,240 Shareholder's Equity 991,860 909,969
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161020005554/en/
ICON plcInvestor Relations, 1-888-381-7923orBrendan Brennan, +
353 1 291 2000Chief Financial OfficerorSimon Holmes, +353 1 291
2000EVP IR & Corporate Developmenthttp://www.iconplc.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024